Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1993
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled studyK S Buser, R A Joss, D Piquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentH J Schmoll, M S Aapro, S Poli-Bigelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyM S Aapro, S M Grunberg, G M Manikhas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2006
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursM S Aapro, D A Cameron, R Pettengell, et al.
Anti-Cancer Drugs|September 1, 1996
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literatureS Piamsomboon, W Termrungruanglert, A P Kudelka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursM S Aapro, J Bohlius, D A Cameron, et al.
Oncology (Williston Park, N.Y.)|August 1, 1997
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancerJ M Nabholtz, B Thuerlimann, W R Bezwoda, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2003
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer GroupM S Aapro, F H van Wijk, M E L van der Burg, et al.
Public Health Genomics|January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancerN T Brewer, J T Defrank, W K Chiu, et al.
Pageof 8